Day: April 30, 2024

As previously announced, HMS Networks has carried out a directed share issue. The directed share issue has resulted in a change in the number of shares and votes in HMS Networks. Prior to the directed share issue, the total number of shares in HMS Networks amounted to 46,818,868, corresponding to 46,818,868 votes. The number of shares and votes has as a result of the directed share issue increased by 3,500,000. As of April 30, 2024, the total number of shares in HMS Networks amounts to 50,318,868, corresponding to 50,318,868 votes.1 For more information, please contact:Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01Joakim Nideborn, CFO HMS, +46 (0)35 710 69 83 This information is such that HMS Networks AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted,...

During the Investor Conference Webinar by Vytautas Sinius, CEO, Donatas Savickas, CFO, Tomas Varenbergas, Head of Investment Management Division and Indre Genytė-Pikčienė, Chief Economist. introduced the Bank’s financial results for Q1 2024 and recent developments and answered the participant questions afterwards. The recording of it can be found on Nasdaq youtube channel there. Presentation and the recording of webinar are also posted on the Bank’s website https://sb.lt/en/investors Šiaulių bankas thanks all participants. If you would like to receive Šiaulių Bankas news for investors directly to your inbox, subscribe to our newsletter.    Additional information:Tomas VarenbergasHead of Investment Management Divisiontomas.varenbergas@sb.lt

MALMÖ, Sweden, April 30, 2024 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the first quarter ended March 31, 2024. Jean-Christophe Flatin, Oatly’s CEO, commented, “I am pleased to report a solid start to the year. In the first quarter, our brand remained strong, our volumes moved in the right direction, our costs structurally came down while also benefiting from timing, and our business became stronger. We are clearly making progress on the three strategic pillars we are focusing on in 2024: bring the Oatly magic to more people, continue our work on the calibration of resources, and focus on execution. Overall, we are off to an encouraging start to the year.” Flatin added, “While we are pleased with this progress...

LONDON, Ontario, April 30, 2024 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQX: ACTHF) (FSE: 9D50), a Canadian technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, has filed its interim consolidated financial results for the three and nine months ended February 29, 2024 and has provided the following highlights. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Ofer Vicus, CEO of Aduro, remarked, “Q3 was a pivotal quarter for the Company as we continued to advance our technology and expand our market presence. The strategic initiatives undertaken not only enhance our technological capabilities but also...

ZeroFox to showcase external cybersecurity platform with newly-released external attack surface management module WASHINGTON, April 30, 2024 (GLOBE NEWSWIRE) — ZeroFox (Nasdaq: ZFOX), a leading provider of external cybersecurity, is exhibiting and speaking at the 2024 RSA Conference in San Francisco, California from May 6-9th. Visit ZeroFox at Booth 1135 to learn how to see and secure all external assets with ZeroFox’s External Attack Surface Management solution, which is generally available as of today. ZeroFox Vice President of Response, Jamie Tolles, and Director of Incident Response, Mari DeGrazia, will present a CISO Boot Camp session on the state of the art for external response best practices and how to limit the impact of a significant cybersecurity incident. The invitation-only session will follow Chatham House Rule to...

BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,968,945 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 4,968,945 shares of common stock and short-term series B warrants to purchase up to 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants...

LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at the Dry Horizons Symposium, a partner meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held May 3, 2024 in Seattle, WA. Date: Friday, May 3, 2024, 2:50-3:45 PM PDTVenue: Four Seasons Seattle, WAPresenter: Gary Jacob, PhD, Chief Executive Officer About Dry Horizons Symposium Uniting clinical leaders...

ASLAN management will present new data from the interim analysis of the TREK-DX study Register here to attend the webinar event on May 7, 2024 at 8:00 AM ETSAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host a virtual Key Opinion Leader (KOL) Event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market”, to be held on Tuesday, May 7, 2024 from 8:00 AM ET to 9:00 AM ET. The event will feature a discussion with Lisa Beck, MD from University of Rochester, Peter Lio, MD from Northwestern University, and Raj Chovatiya,...

Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Second Half of 2024 PETACH TIKVA, Israel, April 30, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the 200th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. The study is now approximately one-third enrolled and is anticipated to continue enrollment at a pace of 1.5 patients per center per month. There are currently approximately 40 centers open and the...

– Company anticipates 10-month review for potential approval in Q1 2025 –– Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually –– Product has patent protection through 2043 – DEER PARK, Ill., April 30, 2024 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of ET-400, Eton’s proprietary patented formulation of hydrocortisone oral solution. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first...